The public health challenge of viral hepatitis in Europe
Hepatitis B and C are stealthy viruses that, if left untreated, silently attack the liver and can cause serious liver disease including cancer decades later. Most viral hepatitis in Europe remains undiagnosed, a scenario evocatively described as a ‘ticking time bomb’ of liver disease-related death and ill-health. Without screening and treatment, mortality from viral hepatitis associated liver disease is predicted to increase and peak around 2030.
The HEPscreen Toolkit has been developed through research and pilot studies and aims to motivate and enable others to respond to this public health challenge through the implementation of effective screening. Watch the animation below for a short introduction to the public health challenge of chronic viral hepatitis in Europe and to find out more about the HEPscreen Toolkit.